<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Transgender women: Evaluation and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Transgender women: Evaluation and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Transgender women: Evaluation and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vin Tangpricha, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joshua D Safer, MD, FACP, FACE</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alvin M Matsumoto, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The terms transgender and gender incongruence describe a situation where an individual's gender identity differs from other aspects of the person's reproductive biology (typically external sexual anatomy at birth). Health care providers should be familiar with commonly used terms  (<a class="graphic graphic_table graphicRef86993" href="/d/graphic/86993.html" rel="external">table 1</a>). Gender identity-affirming care, for those who desire, can include hormone therapy and surgeries, as well as other procedures, such as hair removal or speech therapy [<a href="#rid1">1,2</a>]. </p><p>This topic will use the term transgender in the broadest sense to include any person with incongruence between gender identity and sex recorded at birth (typically based on visualization of external sexual anatomy at birth). The evaluation and management of transgender women are discussed here. The evaluation and management of transgender men, the primary care of the transgender adult, gender diversity in children and adolescents, and gender-affirming surgery are reviewed separately. (See  <a class="medical medical_review" href="/d/html/109911.html" rel="external">"Transgender men: Evaluation and management"</a> and  <a class="medical medical_review" href="/d/html/82964.html" rel="external">"Primary care of transgender individuals"</a> and  <a class="medical medical_review" href="/d/html/83665.html" rel="external">"Gender development and clinical presentation of gender diversity in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/86771.html" rel="external">"Management of transgender and gender-diverse children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/114517.html" rel="external">"Gender-affirming surgery: Male to female"</a>.)</p><p class="headingAnchor" id="H1084578518"><span class="h1">EPIDEMIOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence </strong>–<strong> </strong>Available data suggest that 0.6 percent of the adult population is transgender [<a href="#rid3">3-5</a>]. The prevalence of transgender individuals depends upon the definition. For example, in studies that include only individuals who received hormone therapy, gender-affirming surgery, or had diagnostic codes documenting being transgender, the reported prevalence was 7 to 9 per 100,000 people [<a href="#rid6">6</a>]. However, studies that include transgender status based upon self-report indicate a prevalence of approximately 871 per 100,000 people [<a href="#rid6">6</a>]. </p><p></p><p class="bulletIndent1">In survey-based studies, the self-reported transgender identity was up to 0.5 percent of adults and 2.7 percent in adolescents [<a href="#rid7">7</a>]. One study estimated that there are approximately 25 million transgender individuals worldwide [<a href="#rid8">8</a>]. The number of people seeking gender-affirming care has been increasing, thought to be due to the greater safety transgender people feel coming forward. However, the number seeking treatment is still far below the number anticipated based on anonymous self-report surveys. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evidence for biologic basis </strong>–<strong> </strong>Although the mechanisms remain unclear, there is some evidence for a biologic basis of gender identity [<a href="#rid9">9</a>]. Evidence for a biologic basis for gender identity primarily includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Data on gender identity in intersex individuals (also known as differences of sex development [DSD]).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Data from twins showing greater transgender concordance among identical twins relative to fraternal twins [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neuroanatomical differences associated with gender identity [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Possible influence of prenatal androgen exposure [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">Because sample sizes of most studies on this subject are small, further research is required to assign specific biologic mechanisms for gender identity [<a href="#rid9">9</a>].</p><p></p><p class="headingAnchor" id="H2277441687"><span class="h1">INITIAL PRESENTATION</span><span class="headingEndMark"> — </span>Typically, transgender adults report gender incongruence throughout their lives, starting well before puberty. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age</strong> – Most transgender individuals present in adulthood or late adolescence. Transgender individuals now tend to present at a younger age than in the past, in parallel to greater exposure in public media, societal acceptance, and access to care [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial provider </strong>–<strong> </strong>While some transgender individuals present to mental health providers for diagnosis, it is now common for transgender individuals to see their primary care providers for initial guidance. Other transgender individuals present directly to endocrinologists for hormone prescriptions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coexisting mental health issues </strong>–<strong> </strong>Some transgender individuals have coexisting mood disorders [<a href="#rid14">14</a>]. If these are present, they may improve with gender-affirming hormone therapy [<a href="#rid15">15-17</a>].</p><p></p><p class="headingAnchor" id="H695967249"><span class="h1">DIAGNOSIS</span></p><p>The diagnosis of gender incongruence should be made by qualified health care providers who are familiar with the diagnostic criteria [<a href="#rid18">18,19</a>] and have the necessary experience assessing whether there are mental health concerns that could confound the diagnosis and require treatment before considering hormone therapy  (<a class="graphic graphic_table graphicRef86993" href="/d/graphic/86993.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H1539322596"><span class="h2">Gender incongruence</span><span class="headingEndMark"> — </span>The current criterion for gender incongruence is persistent incongruence between gender identity and sex recorded at birth, typically from visualization of external sexual anatomy at that time.</p><p>The diagnosis of gender incongruence must be made before considering gender-affirming hormone and surgical therapy [<a href="#rid18">18</a>]. Such diagnosis should include screening for co-existing mental health concerns. (See <a class="local">'Pretreatment assessment'</a> below.)</p><p>In addition, it is essential to identify any medical diagnoses that may require treatment before considering hormone therapy [<a href="#rid18">18,19</a>]. (See <a class="local">'Pretreatment assessment'</a> below.)</p><p>Presently, most cases of transgender identity are still diagnosed in adulthood, but increasingly, transgender children and adolescents present for diagnosis and treatment. The clinical presentation of gender diversity in children is reviewed separately. (See  <a class="medical medical_review" href="/d/html/83665.html" rel="external">"Gender development and clinical presentation of gender diversity in children and adolescents", section on 'Clinical presentation'</a>.)</p><p class="headingAnchor" id="H1666820704"><span class="h2">Gender dysphoria</span><span class="headingEndMark"> — </span>Patients also may be diagnosed with gender dysphoria, which is defined as the discomfort arising in some individuals from the incongruence between their gender identities and their sex recorded at birth. Gender dysphoria is currently the diagnostic code in the World Health Organization's International Classification of Diseases-10<sup>th</sup> Revision (ICD-10) for being transgender, but it is a mental health code. Of note, the term gender dysphoria will be removed from the 11<sup>th</sup> Revision (ICD-11), and the code will become "gender incongruence." Mental health codes in transgender individuals will be the same as for other individuals. </p><p>The diagnosis of gender dysphoria is generally done by a mental health professional; however, other health care professionals who have the appropriate experience and training can also diagnose gender dysphoria. Mental health providers typically use the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) to make a diagnosis [<a href="#rid20">20</a>]. Core components of the DSM-5 diagnosis of gender dysphoria include longstanding discomfort with the incongruence between gender identity and external sexual anatomy at birth along with interference with social, school, or other areas of function [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H7"><span class="h1">HORMONAL THERAPY</span></p><p class="headingAnchor" id="H3202886987"><span class="h2">Pretreatment assessment</span></p><p class="headingAnchor" id="H3507458527"><span class="h3">Guidelines/Standards of care</span><span class="headingEndMark"> — </span>Several large medical professional organizations have issued guidelines to assist providers in the evaluation and care of transgender individuals (the World Professional Association for Transgender Health [WPATH] [<a href="#rid7">7</a>], the Endocrine Society [<a href="#rid18">18</a>]  (<a class="graphic graphic_table graphicRef86993" href="/d/graphic/86993.html" rel="external">table 1</a>), and the American College of Obstetricians and Gynecologists [ACOG] [<a href="#rid21">21</a>]).</p><p class="headingAnchor" id="H3286212879"><span class="h3">Criteria for starting hormonal therapy</span><span class="headingEndMark"> — </span>The criteria for starting hormone therapy include [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent, well-documented gender dysphoria/gender incongruence</p><p class="bulletIndent1"><span class="glyph">●</span>Capacity to make a well-informed decision</p><p class="bulletIndent1"><span class="glyph">●</span>Mental health issues, if present, must be addressed sufficiently to move treatment forward </p><p></p><p class="headingAnchor" id="H2558040780"><span class="h3">Address underlying medical issues</span><span class="headingEndMark"> — </span>In addition to these established criteria, clinicians should address any medical conditions or risk factors that could be impacted by hormone therapy, most importantly, cardiovascular risk factors. Several relative contraindications for estrogen require additional evaluation and treatment prior to the initiation of hormones, including a history of breast cancer, venous thromboembolism (VTE), cardiovascular disease, cerebrovascular disease, and severe liver dysfunction. Hyperprolactinemia should be evaluated before starting estradiol therapy. (See <a class="local">'Adverse events'</a> below.)</p><p class="headingAnchor" id="H101306913"><span class="h3">Patient counseling</span><span class="headingEndMark"> — </span>The clinician should discuss a number of issues prior to initiating hormonal therapy, including patient treatment goals, expectations, risks and benefits of therapy, and the potential impact on future fertility.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals </strong>– The usual aim of gender-affirming hormone therapy is to induce physical changes to match gender identity [<a href="#rid22">22</a>]. The treatment goal is to maintain hormone levels in the female physiological range. Administration of estrogens alone will suppress gonadotropin output and, therefore, androgen production, but addition of a second agent that suppresses androgen secretion or action may permit lower estrogen dosing and thus potentially reduce the risk of VTE. (See <a class="local">'Adverse events'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Care team</strong> – Optimally, a transgender patient seeking medical treatment should have access to providers with expertise in transgender-appropriate primary care, gender-affirming hormone therapy, and mental health support.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expectations </strong>–<strong> </strong>Priorities for many transgender women include elimination of facial hair growth, induction of breast formation, a change in voice, and a more female fat/muscle distribution. To accomplish this, a reduction of the biological effects of androgens to female levels is required. Contacts with other transgender individuals who are already undergoing treatment may be helpful in shaping an individual's expectations of what can be achieved and what problems, personally and socially, may arise during treatment. A supportive network of family/caregivers and friends is often important.</p><p></p><p class="bulletIndent1">The physical changes that occur with hormone therapy progress at different rates. Some changes occur within months (softening of skin) while others take years (breast growth)  (<a class="graphic graphic_table graphicRef54189" href="/d/graphic/54189.html" rel="external">table 2</a>). (See <a class="local">'Feminizing effects'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risks and benefits of treatment</strong> – The patient should be fully informed about the risks and benefits of hormonal or surgical therapy [<a href="#rid23">23,24</a>]. (See <a class="local">'Clinical outcomes'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Future fertility</strong> – Transgender women who undergo gender identity-affirming therapy may lose reproductive potential. Thus, before starting any treatment, patients should be encouraged to first consider fertility issues [<a href="#rid19">19</a>] (see <a class="local">'Fertility considerations'</a> below). However, gender-affirming hormone therapy does not reliably suppress spermatogenesis (ie, infertility or subfertility is not uniformly present and not permanent). Therefore, in transgender women who have vaginal intercourse with cisgender women, contraceptive options should be discussed [<a href="#rid25">25-29</a>].</p><p></p><p class="headingAnchor" id="H331025"><span class="h2">Androgen suppression</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">Spironolactone</a>, gonadotropin-releasing hormone (GnRH) agonists, and <a class="drug drug_general" data-topicid="9295" href="/d/drug information/9295.html" rel="external">cyproterone acetate</a> (CPA) (in Europe) have been used as therapies for androgen suppression or inhibition. After gender-affirming genital surgery that includes orchiectomy, antiandrogen therapy may be discontinued [<a href="#rid30">30,31</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spironolactone</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">Spironolactone</a>, a mineralocorticoid receptor antagonist, is the most widely used drug in the United States for transgender women. It is a competitive inhibitor of the androgen receptor as well as an inhibitor of testosterone biosynthesis (by inhibiting 17-hydroxylase and 17,20-lyase) [<a href="#rid32">32-36</a>]. </p><p></p><p class="bulletIndent1">The recommended dose of <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> is 100 to 300 mg/day  (<a class="graphic graphic_table graphicRef69460" href="/d/graphic/69460.html" rel="external">table 3</a>) [<a href="#rid37">37</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>GnRH agonists</strong> – GnRH agonists are an ideal therapy given their ability to suppress gonadotropin and testosterone secretion [<a href="#rid18">18,38</a>]. Historically, they were second-line therapy because of their high cost. However, they are now used routinely for transgender women in some countries, including the UK, but somewhat less so in the United States because of insurance coverage challenges. Dosing of these drugs is found in the table  (<a class="graphic graphic_table graphicRef69460" href="/d/graphic/69460.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CPA </strong>–<strong> </strong>CPA is both a progestin (which suppresses gonadotropins) and an androgen receptor antagonist that is available in most countries but not the United States. Because CPA has been associated with a worse lipid profile, small prolactin elevations, and rare meningiomas, it has become less popular [<a href="#rid39">39,40</a>].</p><p></p><p class="bulletIndent1">If CPA is used, doses should be limited to ≤10 mg/day to avoid the adverse effects [<a href="#rid18">18</a>]. In addition, 10 mg of CPA in combination with estradiol is as effective as higher CPA doses for suppressing serum testosterone concentrations to &lt;2 nmol/L (&lt;58 ng/dL) [<a href="#rid41">41</a>]. <strong> </strong></p><p></p><p class="headingAnchor" id="H10"><span class="h2">Estrogen therapy</span><span class="headingEndMark"> — </span>The usual approach includes estrogen therapy to help suppress endogenous androgen secretion and to replace it with estrogen. There is a wide range of estrogens from which to choose  (<a class="graphic graphic_table graphicRef69460" href="/d/graphic/69460.html" rel="external">table 3</a>). However, 17-beta-estradiol is the preferred estrogen. </p><p>Transdermal estrogen has been associated with a lower risk of venous thromboembolism (VTE) and stroke than oral estrogens in postmenopausal women. However, oral estradiol, which is considerably less expensive than transdermal estradiol, is most often used in transgender women, as they tend to have a low baseline risk for VTE. </p><p>We suggest 17-beta-estradiol over conjugated estrogens so that serum E2 levels can be monitored. </p><p>Transgender women with testis intact may require relatively high doses of estrogens to suppress testosterone into the female range, even with the addition of a GnRH agonist or an antiandrogen agent.</p><p>Typical estradiol regimens include  (<a class="graphic graphic_table graphicRef69460" href="/d/graphic/69460.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Transdermally, 0.025 to 0.2 mg/24 hours. The patch changed once or twice a week, depending on the product.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Orally, 2 to 6 mg/day [<a href="#rid18">18,42</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In Europe, oral 17-beta-estradiol valerate 2 to 4 mg/day is also used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Parenteral estrogens (estradiol valerate or cypionate) are sometimes used  (<a class="graphic graphic_table graphicRef69460" href="/d/graphic/69460.html" rel="external">table 3</a>).</p><p></p><p>We suggest against the use of oral ethinyl estradiol (EE), a potent estrogen used in most combined estrogen-progestin oral contraceptives. It was previously used for transgender women in doses of 50 to 100 mcg/day, but was associated with an excess risk of venous thrombosis and an increased risk of cardiovascular death, particularly in patients over 40 years [<a href="#rid32">32,43-46</a>]. (See <a class="local">'Adverse events'</a> below.)</p><p>Estrogen therapy is administered continuously to avoid symptoms of sex hormone deficiency and to prevent bone loss and osteoporosis [<a href="#rid47">47-49</a>]. The appropriate doses of estrogen are described above and in the table  (<a class="graphic graphic_table graphicRef69460" href="/d/graphic/69460.html" rel="external">table 3</a>).</p><p>Several relative contraindications for estrogen require additional evaluation and treatment prior to the initiation of hormones, including a history of breast cancer, VTE, cardiovascular disease, cerebrovascular disease, and severe liver dysfunction. Hyperprolactinemia should be treated before starting estradiol therapy. (See <a class="local">'Adverse events'</a> below.)</p><p class="headingAnchor" id="H2353216727"><span class="h2">Agents not routinely used</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progestogens </strong>– While progestogens, such as <a class="drug drug_general" data-topicid="9600" href="/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (MPA), are sometimes used to suppress gonadotropins and, therefore, testosterone secretion, we do not suggest them as part of standard hormonal care for transgender women. MPA has been associated with excess cardiovascular and breast cancer risk in older postmenopausal women taking conjugated estrogen. (See  <a class="medical medical_review" href="/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks", section on 'Women's Health Initiative (WHI)'</a>.) </p><p></p><p class="bulletIndent1">The harms associated with CPA in transgender women are noted above. (See <a class="local">'Androgen suppression'</a> above.)</p><p></p><p class="bulletIndent1">Some other progestogens are associated with an increased VTE risk when combined with estrogens [<a href="#rid50">50</a>]<strong>. </strong>A systematic review of progestin use in transgender women found little benefit and increased harm, including lower HDL cholesterol and increased risk of thrombosis [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Finasteride</strong><strong> and </strong><strong>dutasteride</strong><strong> </strong>–<strong> </strong><a class="drug drug_general" data-topicid="8447" href="/d/drug information/8447.html" rel="external">Finasteride</a> inhibits 5-alpha-reductase 2 activity and <a class="drug drug_general" data-topicid="8672" href="/d/drug information/8672.html" rel="external">dutasteride</a> inhibits 5-alpha-reductase 1 and 2 activity, therefore inhibiting conversion of testosterone to the more potent dihydrotestosterone (DHT). They have been used in the management of benign prostatic hyperplasia, prostate cancer, hair loss in men and women, and, occasionally, for hirsutism in women. There are no available data for their use in transgender individuals, where it would be predicted to have little utility if the testosterone levels are low and there is no substrate to generate DHT. (See  <a class="medical medical_review" href="/d/html/3321.html" rel="external">"Male pattern hair loss (androgenetic alopecia in males): Management", section on 'Oral finasteride'</a> and  <a class="medical medical_review" href="/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women", section on 'Antiandrogens'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flutamide</strong><strong> and </strong><strong>nilutamide</strong> – We suggest against the use of nonsteroidal antiandrogens such as <a class="drug drug_general" data-topicid="8471" href="/d/drug information/8471.html" rel="external">flutamide</a> and <a class="drug drug_general" data-topicid="9701" href="/d/drug information/9701.html" rel="external">nilutamide</a>. They increase gonadotropin secretion, causing increased secretion of testosterone and estradiol (only the latter would be desirable). More importantly, flutamide has been associated with hepatotoxicity. (See  <a class="medical medical_review" href="/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women", section on 'Antiandrogens'</a>.)</p><p></p><p class="headingAnchor" id="H3444626406"><span class="h2">Monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequency </strong>– Clinical monitoring of transgender women taking hormone therapy should occur with each dose titration, typically every three months during the first year. When stable, typically after the first year, monitoring should be once or twice yearly  (<a class="graphic graphic_table graphicRef67967" href="/d/graphic/67967.html" rel="external">table 4</a>). In addition to clinical assessment that the patient is comfortable with the regimen, monitoring should include the following:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biochemical testing</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum total testosterone concentrations to determine when the level is within the female range if the patient desires a conventional regimen. Optimally, testosterone should be measured using mass spectrometry assay [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients using <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a>, we measure a serum potassium concentration after the first month of treatment and after dose titrations. More frequent serum potassium measurements are not necessary, given the low prevalence of hyperkalemia in transgender women with normal kidney function taking spironolactone  (<a class="graphic graphic_table graphicRef67967" href="/d/graphic/67967.html" rel="external">table 4</a>) [<a href="#rid52">52,53</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>E2 concentrations should be monitored to avoid supraphysiologic levels (eg, maintain levels &lt;200 pg/mL [734 pmol/L])  (<a class="graphic graphic_table graphicRef67967" href="/d/graphic/67967.html" rel="external">table 4</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some guidelines suggest monitoring serum prolactin levels because rare cases of elevated prolactin have been described in transgender women who have received gender-affirming hormone therapy [<a href="#rid18">18</a>]. However, only cyproterone acetate-containing regimens have been associated with prolactin elevations [<a href="#rid54">54</a>]. In the only studies of transgender women using <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> in addition to estrogen, no similar impact on prolactin has been observed [<a href="#rid55">55,56</a>]. And in cisgender females, estrogen does not increase serum prolactin, nor does it cause prolactinomas. We suggest measuring a baseline prolactin level before starting gender-affirming hormone treatment in order to treat pre-existing hyperprolactinemia. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer screening</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the absence of transgender-specific data, standard breast screening guidelines developed for women should be followed. (See  <a class="medical medical_review" href="/d/html/82964.html" rel="external">"Primary care of transgender individuals", section on 'Breast cancer'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All individuals with prostate tissue require monitoring for prostate carcinoma. In the absence of transgender-specific data, standard prostate screening guidelines developed for cisgender men should be followed [<a href="#rid18">18</a>], even though prostate cancer might be rare in transgender women who have undergone genital surgery that includes gonadectomy. (See  <a class="medical medical_review" href="/d/html/82964.html" rel="external">"Primary care of transgender individuals", section on 'Prostate cancer'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone health </strong>– For transgender women at low risk, the Endocrine Society suggests screening for osteoporosis conducted at age 60 years or earlier in those who are not compliant with hormone therapy [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/82964.html" rel="external">"Primary care of transgender individuals"</a>.)</p><p></p><p class="headingAnchor" id="H384457094"><span class="h1">CLINICAL OUTCOMES</span></p><p class="headingAnchor" id="H3650613053"><span class="h2">Feminizing effects</span><span class="headingEndMark"> — </span>Although a goal of therapy is to reduce the hormonally induced male secondary sex characteristics (if puberty is not delayed with gonadotropin-releasing hormone [GnRH] agonists), complete elimination is not possible. In transgender women, effects of androgens on the skeleton, such as greater height, size and shape of hands, feet, jaws, and pelvis, and voice (laryngeal prominence), cannot be reversed.</p><p>However, there are many changes that do occur  (<a class="graphic graphic_table graphicRef54189" href="/d/graphic/54189.html" rel="external">table 2</a>). The changes during the first three to six months include a possible decrease in sexual desire and decreased rates of growth of facial and body hair. There will also be some initial growth of breast tissue, a decrease in oiliness of the skin, and early redistribution of fat mass [<a href="#rid18">18</a>]. Hematocrit/hemoglobin levels fall as might be expected with lower levels of testosterone [<a href="#rid57">57</a>].</p><p>The main clinical outcomes include  (<a class="graphic graphic_table graphicRef54189" href="/d/graphic/54189.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sexual hair</strong> – Adult male beard growth is very resistant to inhibition by combined hormonal intervention and, especially in individuals with European ancestry, additional measures such as laser hair removal or electrolysis are usually necessary. Eflornithine 12.9% cream can slow facial growth, but its use is somewhat limited by costs and continuous twice daily application that is required for the effect to be sustained. (See  <a class="medical medical_review" href="/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women", section on 'Role of direct hair removal methods'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breast development</strong> – Breast formation starts almost immediately after initiation of estrogen administration and is typically maximal at two years [<a href="#rid32">32,58-60</a>]. Some report nipple tenderness and discomfort during breast growth. Androgens have an inhibitory effect on breast formation, and therefore, estrogens will be most effective when testosterone has been lowered to the female range.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin</strong> – Decreased testosterone leads to a decreased activity of the sebaceous glands and may result in dry skin or brittle nails [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Body composition</strong> – Following a decrease in testosterone, there is an increase in subcutaneous fat and a decrease in lean body mass [<a href="#rid62">62</a>]. Body weight usually increases in parallel with an increase in body mass index (BMI) [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testes</strong> – Atrophy of the testes (if not surgically removed) occurs over many years. Lacking gonadotropic stimulation, the testes become atrophic and may occasionally enter the inguinal canal, which may cause discomfort.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prostate</strong> – Atrophy of the prostate also occurs over many years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Voice</strong> – Antiandrogens and estrogens have no effect on the properties of the voice, so transgender women may choose to consult a specialized phoniatric center for speech therapy. Pitch and resonance are the usual focus of therapy because the combination of these two voice characteristics are thought to account for the majority of how a speaker's gender is perceived [<a href="#rid64">64</a>]. Speech therapy may lead to more feminine speech [<a href="#rid65">65</a>]. Laryngeal surgery is reported by some to change the pitch of the voice but reduces its range.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sexual function</strong> – Feminizing hormone therapy may reduce sexual desire, reduce erectile function, and decrease ejaculation among transgender women [<a href="#rid66">66</a>]. Some transgender women choose to reduce hormone doses to balance the degree of feminization with the level of sexual function, while others report no need for dose adjustments. Following genital surgery, sexual function (sexual desire, arousal, pain with sex, and orgasm) is variable for transgender women and depends on preoperative sexual function, the type of surgery performed, and hormonal status [<a href="#rid67">67</a>].</p><p></p><p class="headingAnchor" id="H1537695997"><span class="h2">Psychosocial outcomes</span><span class="headingEndMark"> — </span>Transgender treatment that includes hormonal therapy results in significant improvement in quality-of-life and psychosocial outcomes, as illustrated in a meta-analysis of 28 studies that enrolled 1833 transgender individuals (1093 transgender women, 801 transgender men) who underwent gender-affirming treatment that included hormones [<a href="#rid15">15</a>]. Evidence from the pooled analysis suggested improvements in gender dysphoria symptoms, psychological functioning, sexual function, and overall quality of life. Improvements in quality of life and a decrease in depression and anxiety were reported in a meta-analysis of 20 studies [<a href="#rid68">68</a>]. </p><p class="headingAnchor" id="H1670899541"><span class="h2">Bone health</span><span class="headingEndMark"> — </span>The International Society for Clinical Densitometry (ISCD) recommends using T-scores based on the adjusted female reference database to diagnose osteoporosis for transgender women greater than age 50 [<a href="#rid69">69</a>]. Z-scores can be used for younger individuals using the reference database that matches their gender identity. (See  <a class="medical medical_review" href="/d/html/82964.html" rel="external">"Primary care of transgender individuals"</a>.)</p><p class="headingAnchor" id="H768005246"><span class="h2">Adverse events</span></p><p class="headingAnchor" id="H3242655107"><span class="h3">Cardiovascular</span><span class="headingEndMark"> — </span>The increased risk of cardiovascular events reported in early studies of transgender women receiving gender-affirming hormone therapy was likely in part related to the use of the potent oral estrogen, ethinyl estradiol [<a href="#rid46">46,70,71</a>]. </p><p>Observational studies suggest that the use of estrogen by transgender women may confer an increased risk for cardiovascular disease (CVD) [<a href="#rid72">72-76</a>], perhaps due to a deleterious effect on CVD risk factors [<a href="#rid77">77,78</a>]. Persistent gender minority stress has been proposed as one possible factor for the potentially increased cardiovascular risk in transgender women [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/d/html/82964.html" rel="external">"Primary care of transgender individuals", section on 'Cardiovascular disease'</a> and  <a class="medical medical_review" href="/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p>Some epidemiological studies have suggested that transgender women have a higher risk of myocardial infarction (MI) and ischemic strokes, compared with cisgender women. However, in a meta-analysis of 29 studies including over 3200 transgender women receiving hormone therapy, increases in serum triglycerides were observed (with oral estrogens), but very few MI or strokes were seen [<a href="#rid75">75</a>]. Stroke occurred in 8 of 859 patients (3 percent) and myocardial infarction in 14 of 1073 (1 percent). Some of these events occurred in centers where high doses of oral ethinyl estradiol (100 mcg/day) were originally used [<a href="#rid43">43</a>].</p><p>Until further data are available, risk factors for CVD should be reviewed in transgender individuals treated with hormones [<a href="#rid37">37,74</a>]. (See  <a class="medical medical_review" href="/d/html/82964.html" rel="external">"Primary care of transgender individuals", section on 'Cardiovascular disease'</a> and  <a class="medical medical_review" href="/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H2032297574"><span class="h3">Venous thromboembolism</span></p><p class="bulletIndent1"><span class="glyph">●</span>Studies have demonstrated an increased risk of venous thromboembolism (VTE) in transgender individuals receiving gender-affirming hormone therapy, particularly in those taking ethinyl estradiol [<a href="#rid80">80</a>]. In one cohort, no excess risk was seen in transgender women taking estrogen preparations other than ethinyl estradiol [<a href="#rid46">46</a>]. Based upon these observations, current guidelines recommend against the use of ethinyl estradiol [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the meta-analysis of 29 studies described above [<a href="#rid75">75</a>], 56 of 1767 transgender women experienced VTE (3 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second meta-analysis of 18 studies including over 11,000 transgender women undergoing gender affirming hormone therapy, the overall rate of VTE was 2 percent [<a href="#rid81">81</a>]. No events were seen in those under age 37.5 years, while the VTE rate in those over age 37.5 years was 3 percent. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an electronic medical record-based cohort study that included 2842 transgender women matched to approximately 48,000 cisgender men and 48,000 cisgender women, the transgender women had a higher rate of VTE (5.5/1000 years) than both control groups [<a href="#rid82">82</a>]. Most transgender women were receiving oral estradiol; the average maximum daily dose was 4 mg (range 1 to 10 mg) and was the same for those who did or did not have a VTE. </p><p></p><p class="bulletIndent1">The difference seemed more pronounced with increased follow-up, with two- and eight-year absolute risk differences of 4.1 and 16.7 per 1000 persons relative to cisgender men and 3.4 and 13.7 per 1000 persons relative to cisgender women. This pattern is different from that seen in postmenopausal women taking hormone therapy, where VTE risk is highest in the first year of use and then declines. This suggests that long-term monitoring is important in this population. (See  <a class="medical medical_review" href="/d/html/7409.html" rel="external">"Menopausal hormone therapy and cardiovascular risk", section on 'Venous thromboembolism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gender-affirming estrogen therapy is typically discontinued in the perioperative period to minimize the risk of VTE. However, a retrospective study from a single center reported that VTE rates were similar in patients who discontinued estrogen compared with those who continued estrogen through the perioperative period [<a href="#rid83">83</a>]. This issue is reviewed in more detail separately. (See  <a class="medical medical_review" href="/d/html/114517.html" rel="external">"Gender-affirming surgery: Male to female", section on 'Perioperative management of systemic estrogen therapy'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of thrombophilias appears to be the same in the transgender population as the general population. Therefore, routine pretreatment screening for thrombophilias is not suggested. </p><p></p><p class="headingAnchor" id="H2728322199"><span class="h3">Other</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Triglycerides </strong>–<strong> </strong>A small increased risk of elevated triglycerides has been reported during estrogen treatment. Very high levels of triglycerides (&gt;2000 mg/dL [22.59 mmol/L]) would place patients at risk for acute pancreatitis. A meta-analysis of 16 studies concluded that cross-sex hormone therapies slightly increase serum triglycerides [<a href="#rid75">75</a>]. Oral estrogens should be avoided in those with known familial hypertriglyceridemia [<a href="#rid84">84,85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mortality</strong> – The increased mortality rates in transgender women observed in early reports may be related to morbidity due to failure to treat rather than from the treatment itself. For example, in a report of 966 transgender women and 365 transgender men, the mortality rate was 51 percent higher in the transgender individuals compared with the general population, mainly due to drug abuse, human immunodeficiency virus (HIV), cardiovascular disease, and suicide [<a href="#rid46">46</a>]. Users of oral ethinyl estradiol, an estrogen that is no longer used for transgender women, had a threefold excess risk of cardiovascular death.</p><p></p><p class="bulletIndent1">Current estimates of mortality rates in one study of transgender persons was approximately 9.3 percent over a 10-year follow-up period. The causes of death were similar to those in the United States population over the same study period with the exception of suicide, which was higher in the transgender individuals compared with the general population [<a href="#rid86">86</a>]. An update of one cohort found increased mortality rates in transgender women but not transgender men, compared with the expected mortality rates among cisgender men and women [<a href="#rid87">87,88</a>]. They found increased death rates among transgender women in cardiovascular diseases, infections, cancer, and non-natural causes (including suicide) compared with cisgender men and women. </p><p></p><p class="headingAnchor" id="H1860228424"><span class="h1">FERTILITY CONSIDERATIONS</span><span class="headingEndMark"> — </span>Transgender individuals who are considering gender-affirming hormone therapy or surgery should be encouraged to consider fertility issues [<a href="#rid89">89,90</a>]. Sperm cryopreservation (ideally before initiating hormone therapy) is available for transgender women [<a href="#rid91">91</a>]. Unfortunately, only a small percentage of patients are taking advantage of sperm cryopreservation. In one report of 99 transgender women, 75 individuals considered banking sperm, but only 9 actually did [<a href="#rid92">92,93</a>]. (See  <a class="medical medical_review" href="/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men", section on 'Semen cryopreservation'</a>.)</p><p class="headingAnchor" id="H3494664244"><span class="h1">GENDER-AFFIRMING SURGERY</span><span class="headingEndMark"> — </span>Individuals can and do live successfully in the gender role that aligns with their gender identity without gender-affirming surgery. The steps that are required before initiating surgical treatment are reviewed above. The approach to gender-affirming surgery in these patients is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/114517.html" rel="external">"Gender-affirming surgery: Male to female"</a>.)</p><p class="headingAnchor" id="H3654077874"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117789.html" rel="external">"Society guideline links: Transgender health"</a>.)</p><p class="headingAnchor" id="H28836485"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/86378.html" rel="external">"Patient education: Being transgender (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H331321"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions </strong>–<strong> </strong>Transgender is an umbrella term that is used to describe individuals with gender diversity; it includes individuals whose gender identity is different from their sex recorded at birth. Such individuals may define themselves as transmasculine, transfeminine, or nonbinary (the last term meaning they have gender identity attributes that are both male and female)  (<a class="graphic graphic_table graphicRef86993" href="/d/graphic/86993.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>Transgender individuals should have their gender incongruence confirmed by medical professionals with appropriate experience. It is necessary to ascertain that there is persistent gender incongruence and that the person is able to understand the risks and benefits of intervention. (See <a class="local">'Initial presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hormone therapy </strong>–<strong> </strong>Before initiating transgender hormonal or surgical treatment, the clinician should counsel the patient about risks and benefits of the hormonal or surgical therapy, including impact on fertility, as well as realistic expectations about outcomes. (See <a class="local">'Patient counseling'</a> above.)</p><p></p><p class="bulletIndent1">For estrogen therapy in transgender women, we suggest either transdermal or oral 17-beta-estradiol (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We suggest against the use of ethinyl estradiol because of an increased risk of venous thromboembolism (VTE) (see <a class="local">'Estrogen therapy'</a> above). In addition, we add a gonadotropin-releasing hormone (GnRH) agonist for androgen suppression, <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a>, or low doses of CPA to inhibit androgen action  (<a class="graphic graphic_table graphicRef69460" href="/d/graphic/69460.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1">Transgender women receiving hormone therapy should be monitored to avoid supraphysiologic serum estradiol (E2) concentrations (eg, maintain E2 levels &lt;200 pg/mL [734 pmol/L]) and to verify that serum testosterone levels reach the physiologic female range  (<a class="graphic graphic_table graphicRef67967" href="/d/graphic/67967.html" rel="external">table 4</a>). Serum potassium should be checked when titrating <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a>. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>–<strong> </strong>For transgender women, the most important risk associated with estrogen therapy is VTE, seen primarily with ethinyl estradiol. (See <a class="local">'Venous thromboembolism'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening guidelines </strong>–<strong> </strong>We agree with the Endocrine Society guidelines that transgender individuals should follow the screening guidelines for all tissues present, independent of gender identity. For example, prostate cancer screening should be done in individuals with a prostate. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery </strong>–<strong> </strong>A detailed review of gender-affirming surgery is found separately. (See  <a class="medical medical_review" href="/d/html/114517.html" rel="external">"Gender-affirming surgery: Male to female"</a>.)</p><p></p><p class="headingAnchor" id="H15570543"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Louis JG Gooren, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgend 2012; 13:165.</a></li><li><a class="nounderline abstract_t">Safer JD, Tangpricha V. Care of the Transgender Patient. Ann Intern Med 2019; 171:ITC1.</a></li><li><a class="nounderline abstract_t">Conron KJ, Scott G, Stowell GS, Landers SJ. Transgender health in Massachusetts: results from a household probability sample of adults. Am J Public Health 2012; 102:118.</a></li><li><a class="nounderline abstract_t">Reisner SL, Conron KJ, Tardiff LA, et al. Monitoring the health of transgender and other gender minority populations: validity of natal sex and gender identity survey items in a U.S. national cohort of young adults. BMC Public Health 2014; 14:1224.</a></li><li class="breakAll">https://williamsinstitute.law.ucla.edu/wp-content/uploads/How-Many-Adults-Identify-as-Transgender-in-the-United-States.pdf (Accessed on May 23, 2018).</li><li><a class="nounderline abstract_t">Collin L, Reisner SL, Tangpricha V, Goodman M. Prevalence of Transgender Depends on the "Case" Definition: A Systematic Review. J Sex Med 2016; 13:613.</a></li><li><a class="nounderline abstract_t">Coleman E, Radix AE, Bouman WP, et al. Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health 2022; 23:259.</a></li><li><a class="nounderline abstract_t">Winter S, Diamond M, Green J, et al. Transgender people: health at the margins of society. Lancet 2016; 388:390.</a></li><li><a class="nounderline abstract_t">Saraswat A, Weinand JD, Safer JD. Evidence supporting the biologic nature of gender identity. Endocr Pract 2015; 21:199.</a></li><li><a class="nounderline abstract_t">Heylens G, De Cuypere G, Zucker KJ, et al. Gender identity disorder in twins: a review of the case report literature. J Sex Med 2012; 9:751.</a></li><li><a class="nounderline abstract_t">Luders E, Sánchez FJ, Tosun D, et al. Increased Cortical Thickness in Male-to-Female Transsexualism. J Behav Brain Sci 2012; 2:357.</a></li><li><a class="nounderline abstract_t">Wilson JD. The role of androgens in male gender role behavior. Endocr Rev 1999; 20:726.</a></li><li><a class="nounderline abstract_t">Leinung MC, Urizar MF, Patel N, Sood SC. Endocrine treatment of transsexual persons: extensive personal experience. Endocr Pract 2013; 19:644.</a></li><li><a class="nounderline abstract_t">Terada S, Matsumoto Y, Sato T, et al. Factors predicting psychiatric co-morbidity in gender-dysphoric adults. Psychiatry Res 2012; 200:469.</a></li><li><a class="nounderline abstract_t">Murad MH, Elamin MB, Garcia MZ, et al. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin Endocrinol (Oxf) 2010; 72:214.</a></li><li><a class="nounderline abstract_t">Smith YL, van Goozen SH, Cohen-Kettenis PT. Adolescents with gender identity disorder who were accepted or rejected for sex reassignment surgery: a prospective follow-up study. J Am Acad Child Adolesc Psychiatry 2001; 40:472.</a></li><li><a class="nounderline abstract_t">Colizzi M, Costa R, Todarello O. Transsexual patients' psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: results from a longitudinal study. Psychoneuroendocrinology 2014; 39:65.</a></li><li><a class="nounderline abstract_t">Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017; 102:3869.</a></li><li class="breakAll">World Professional Association for Transgender Health. Standards of care for gender identity disorders. http://wpath.org/publications_standards.cfm (Accessed on September 13, 2011).</li><li class="breakAll">American Psychiatric Association. Gender dysphoria. In: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association, Arlington, VA 2013. p.451.</li><li class="breakAll">http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Health-Care-for-Underserved-Women/Health-Care-for-Transgender-Individuals (Accessed on August 03, 2016).</li><li><a class="nounderline abstract_t">Gooren L. Hormone treatment of the adult transsexual patient. Horm Res 2005; 64 Suppl 2:31.</a></li><li><a class="nounderline abstract_t">Gooren LJ. Clinical practice. Care of transsexual persons. N Engl J Med 2011; 364:1251.</a></li><li><a class="nounderline abstract_t">Weinand JD, Safer JD. Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals. J Clin Transl Endocrinol 2015; 2:55.</a></li><li><a class="nounderline abstract_t">Mancini I, Alvisi S, Gava G, et al. Contraception across transgender. Int J Impot Res 2020; 33:710.</a></li><li><a class="nounderline abstract_t">Schneider F, Kliesch S, Schlatt S, Neuhaus N. Andrology of male-to-female transsexuals: influence of cross-sex hormone therapy on testicular function. Andrology 2017; 5:873.</a></li><li><a class="nounderline abstract_t">Jindarak S, Nilprapha K, Atikankul T, et al. Spermatogenesis Abnormalities following Hormonal Therapy in Transwomen. Biomed Res Int 2018; 2018:7919481.</a></li><li><a class="nounderline abstract_t">Kent MA, Winoker JS, Grotas AB. Effects of Feminizing Hormones on Sperm Production and Malignant Changes: Microscopic Examination of Post Orchiectomy Specimens in Transwomen. Urology 2018; 121:93.</a></li><li><a class="nounderline abstract_t">de Nie I, van Mello NM, Vlahakis E, et al. Successful restoration of spermatogenesis following gender-affirming hormone therapy in transgender women. Cell Rep Med 2023; 4:100858.</a></li><li><a class="nounderline abstract_t">Zitzmann M, Erren M, Kamischke A, et al. Endogenous progesterone and the exogenous progestin norethisterone enanthate are associated with a proinflammatory profile in healthy men. J Clin Endocrinol Metab 2005; 90:6603.</a></li><li><a class="nounderline abstract_t">Angus L, Leemaqz S, Ooi O, et al. Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy. Endocr Connect 2019; 8:935.</a></li><li><a class="nounderline abstract_t">Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 2003; 88:3467.</a></li><li><a class="nounderline abstract_t">Tangpricha V, Ducharme SH, Barber TW, Chipkin SR. Endocrinologic treatment of gender identity disorders. Endocr Pract 2003; 9:12.</a></li><li><a class="nounderline abstract_t">Menard RH, Stripp B, Gillette JR. Spironolactone and testicular cytochrome P-450: decreased testosterone formation in several species and changes in hepatic drug metabolism. Endocrinology 1974; 94:1628.</a></li><li><a class="nounderline abstract_t">Spironolactone and endocrine dysfunction. Ann Intern Med 1976; 85:630.</a></li><li><a class="nounderline abstract_t">Stripp B, Taylor AA, Bartter FC, et al. Effect of spironolactone on sex hormones in man. J Clin Endocrinol Metab 1975; 41:777.</a></li><li><a class="nounderline abstract_t">Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132.</a></li><li><a class="nounderline abstract_t">Dittrich R, Binder H, Cupisti S, et al. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Exp Clin Endocrinol Diabetes 2005; 113:586.</a></li><li><a class="nounderline abstract_t">Nota NM, Wiepjes CM, de Blok CJM, et al. The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment. Brain 2018; 141:2047.</a></li><li><a class="nounderline abstract_t">Patel KT, Adeel S, Rodrigues Miragaya J, Tangpricha V. Progestogen Use in Gender-Affirming Hormone Therapy: A Systematic Review. Endocr Pract 2022; 28:1244.</a></li><li><a class="nounderline abstract_t">Kuijpers SME, Wiepjes CM, Conemans EB, et al. Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study. J Clin Endocrinol Metab 2021; 106:e3936.</a></li><li><a class="nounderline abstract_t">Chantrapanichkul P, Stevenson MO, Suppakitjanusant P, et al. SERUM HORMONE CONCENTRATIONS IN TRANSGENDER INDIVIDUALS RECEIVING GENDER-AFFIRMING HORMONE THERAPY: A LONGITUDINAL RETROSPECTIVE COHORT STUDY. Endocr Pract 2021; 27:27.</a></li><li><a class="nounderline abstract_t">van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 1997; 47:337.</a></li><li><a class="nounderline abstract_t">Toorians AW, Thomassen MC, Zweegman S, et al. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab 2003; 88:5723.</a></li><li><a class="nounderline abstract_t">Asscheman H, T'Sjoen G, Lemaire A, et al. Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review. Andrologia 2014; 46:791.</a></li><li><a class="nounderline abstract_t">Asscheman H, Giltay EJ, Megens JA, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2011; 164:635.</a></li><li><a class="nounderline abstract_t">van Kesteren P, Lips P, Gooren LJ, et al. Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clin Endocrinol (Oxf) 1998; 48:347.</a></li><li><a class="nounderline abstract_t">Mueller A, Dittrich R, Binder H, et al. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone. Eur J Endocrinol 2005; 153:107.</a></li><li><a class="nounderline abstract_t">Ruetsche AG, Kneubuehl R, Birkhaeuser MH, Lippuner K. Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study. Osteoporos Int 2005; 16:791.</a></li><li><a class="nounderline abstract_t">Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2019; 364:k4810.</a></li><li><a class="nounderline abstract_t">La'ulu SL, Kalp KJ, Straseski JA. How low can you go? Analytical performance of five automated testosterone immunoassays. Clin Biochem 2018; 58:64.</a></li><li><a class="nounderline abstract_t">Gupta P, Suppakitjanusant P, Stevenson M, et al. Potassium Concentrations in Transgender Women Using Spironolactone: A Retrospective Chart Review. Endocr Pract 2022; 28:1113.</a></li><li><a class="nounderline abstract_t">Plovanich M, Weng QY, Mostaghimi A. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne. JAMA Dermatol 2015; 151:941.</a></li><li><a class="nounderline abstract_t">Nota NM, Dekker MJ, Klaver M, et al. Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons. Andrologia 2016.</a></li><li><a class="nounderline abstract_t">Bisson JR, Chan KJ, Safer JD. PROLACTIN LEVELS DO NOT RISE AMONG TRANSGENDER WOMEN TREATED WITH ESTRADIOL AND SPIRONOLACTONE. Endocr Pract 2018; 24:646.</a></li><li><a class="nounderline abstract_t">Sofer Y, Yaish I, Yaron M, et al. Differential Endocrine and Metabolic Effects of Testosterone Suppressive Agents in Transgender Women. Endocr Pract 2020; 26:883.</a></li><li><a class="nounderline abstract_t">Harper J, O'Donnell E, Sorouri Khorashad B, et al. How does hormone transition in transgender women change body composition, muscle strength and haemoglobin? Systematic review with a focus on the implications for sport participation. Br J Sports Med 2021; 55:865.</a></li><li><a class="nounderline abstract_t">Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol (Oxf) 2003; 59:409.</a></li><li><a class="nounderline abstract_t">Gooren LJ, Giltay EJ. Men and women, so different, so similar: observations from cross-sex hormone treatment of transsexual subjects. Andrologia 2014; 46:570.</a></li><li><a class="nounderline abstract_t">Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008; 93:19.</a></li><li><a class="nounderline abstract_t">Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab 2000; 85:2913.</a></li><li><a class="nounderline abstract_t">Lapauw B, Taes Y, Simoens S, et al. Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone 2008; 43:1016.</a></li><li><a class="nounderline abstract_t">Suppakitjanusant P, Ji Y, Stevenson MO, et al. Effects of gender affirming hormone therapy on body mass index in transgender individuals: A longitudinal cohort study. J Clin Transl Endocrinol 2020; 21:100230.</a></li><li><a class="nounderline abstract_t">Hancock AB, Garabedian LM. Transgender voice and communication treatment: a retrospective chart review of 25 cases. Int J Lang Commun Disord 2013; 48:54.</a></li><li><a class="nounderline abstract_t">de Bruin MD, Coerts MJ, Greven AJ. Speech therapy in the management of male-to-female transsexuals. Folia Phoniatr Logop 2000; 52:220.</a></li><li><a class="nounderline abstract_t">Feldman J, Safer J. Hormone therapy in adults: suggested revisions to the sixth version of the standards of care. Int J Transgend 2009; 11:146.</a></li><li><a class="nounderline abstract_t">Klein C, Gorzalka BB. Sexual functioning in transsexuals following hormone therapy and genital surgery: a review. J Sex Med 2009; 6:2922.</a></li><li><a class="nounderline abstract_t">Baker KE, Wilson LM, Sharma R, et al. Hormone Therapy, Mental Health, and Quality of Life Among Transgender People: A Systematic Review. J Endocr Soc 2021; 5:bvab011.</a></li><li><a class="nounderline abstract_t">Rosen HN, Hamnvik OR, Jaisamrarn U, et al. Bone Densitometry in Transgender and Gender Non-Conforming (TGNC) Individuals: 2019 ISCD Official Position. J Clin Densitom 2019; 22:544.</a></li><li><a class="nounderline abstract_t">Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study. Eur J Endocrinol 2013; 169:471.</a></li><li><a class="nounderline abstract_t">Wierckx K, Mueller S, Weyers S, et al. Long-term evaluation of cross-sex hormone treatment in transsexual persons. J Sex Med 2012; 9:2641.</a></li><li><a class="nounderline abstract_t">Gooren LJ, Wierckx K, Giltay EJ. Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern. Eur J Endocrinol 2014; 170:809.</a></li><li><a class="nounderline abstract_t">Connelly PJ, Marie Freel E, Perry C, et al. Gender-Affirming Hormone Therapy, Vascular Health and Cardiovascular Disease in Transgender Adults. Hypertension 2019; 74:1266.</a></li><li><a class="nounderline abstract_t">Streed CG Jr, Harfouch O, Marvel F, et al. Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review. Ann Intern Med 2017; 167:256.</a></li><li><a class="nounderline abstract_t">Maraka S, Singh Ospina N, Rodriguez-Gutierrez R, et al. Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2017; 102:3914.</a></li><li><a class="nounderline abstract_t">Nota NM, Wiepjes CM, de Blok CJM, et al. Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy. Circulation 2019; 139:1461.</a></li><li><a class="nounderline abstract_t">Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience. J Clin Endocrinol Metab 2008; 93:19.</a></li><li><a class="nounderline abstract_t">Elamin MB, Garcia MZ, Murad MH, et al. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol (Oxf) 2010; 72:1.</a></li><li><a class="nounderline abstract_t">Streed CG Jr, Beach LB, Caceres BA, et al. Assessing and Addressing Cardiovascular Health in People Who Are Transgender and Gender Diverse: A Scientific Statement From the American Heart Association. Circulation 2021; 144:e136.</a></li><li><a class="nounderline abstract_t">Goldstein Z, Khan M, Reisman T, Safer JD. Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy. J Blood Med 2019; 10:209.</a></li><li><a class="nounderline abstract_t">Totaro M, Palazzi S, Castellini C, et al. Risk of Venous Thromboembolism in Transgender People Undergoing Hormone Feminizing Therapy: A Prevalence Meta-Analysis and Meta-Regression Study. Front Endocrinol (Lausanne) 2021; 12:741866.</a></li><li><a class="nounderline abstract_t">Getahun D, Nash R, Flanders WD, et al. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study. Ann Intern Med 2018; 169:205.</a></li><li><a class="nounderline abstract_t">Kozato A, Fox GWC, Yong PC, et al. No Venous Thromboembolism Increase Among Transgender Female Patients Remaining on Estrogen for Gender-Affirming Surgery. J Clin Endocrinol Metab 2021; 106:e1586.</a></li><li><a class="nounderline abstract_t">Goldenberg NM, Wang P, Glueck CJ. An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. Clin Chim Acta 2003; 332:11.</a></li><li><a class="nounderline abstract_t">Goldberg RB, Chait A. A Comprehensive Update on the Chylomicronemia Syndrome. Front Endocrinol (Lausanne) 2020; 11:593931.</a></li><li><a class="nounderline abstract_t">Blosnich JR, Brown GR, Wojcio S, et al. Mortality Among Veterans with Transgender-Related Diagnoses in the Veterans Health Administration, FY2000-2009. LGBT Health 2014; 1:269.</a></li><li><a class="nounderline abstract_t">de Blok CJ, Wiepjes CM, van Velzen DM, et al. Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria. Lancet Diabetes Endocrinol 2021; 9:663.</a></li><li><a class="nounderline abstract_t">Tangpricha V. Health disparities in transgender people. Lancet Diabetes Endocrinol 2021; 9:641.</a></li><li><a class="nounderline abstract_t">TʼSjoen G, Van Caenegem E, Wierckx K. Transgenderism and reproduction. Curr Opin Endocrinol Diabetes Obes 2013; 20:575.</a></li><li><a class="nounderline abstract_t">Wallace SA, Blough KL, Kondapalli LA. Fertility preservation in the transgender patient: expanding oncofertility care beyond cancer. Gynecol Endocrinol 2014; 30:868.</a></li><li><a class="nounderline abstract_t">Sermondade N, Benaloun E, Berthaut I, et al. Reproductive functions and fertility preservation in transgender women: a French case series. Reprod Biomed Online 2021; 43:339.</a></li><li><a class="nounderline abstract_t">Mayhew AC, Gomez-Lobo V. Fertility Options for the Transgender and Gender Nonbinary Patient. J Clin Endocrinol Metab 2020; 105:3335.</a></li><li><a class="nounderline abstract_t">Auer MK, Fuss J, Nieder TO, et al. Desire to Have Children Among Transgender People in Germany: A Cross-Sectional Multi-Center Study. J Sex Med 2018; 15:757.</a></li></ol></div><div id="topicVersionRevision">Topic 7456 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31261405" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Care of the Transgender Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22095354" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Transgender health in Massachusetts: results from a household probability sample of adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25427573" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Monitoring the health of transgender and other gender minority populations: validity of natal sex and gender identity survey items in a U.S. national cohort of young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25427573" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Monitoring the health of transgender and other gender minority populations: validity of natal sex and gender identity survey items in a U.S. national cohort of young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27045261" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence of Transgender Depends on the "Case" Definition: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Standards of care for the health of transgender and gender diverse people, version 8</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27323925" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Transgender people: health at the margins of society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25667367" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Evidence supporting the biologic nature of gender identity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22146048" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Gender identity disorder in twins: a review of the case report literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23724358" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Increased Cortical Thickness in Male-to-Female Transsexualism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10529900" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The role of androgens in male gender role behavior.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23512380" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Endocrine treatment of transsexual persons: extensive personal experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22884214" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Factors predicting psychiatric co-morbidity in gender-dysphoric adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19473181" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11314574" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Adolescents with gender identity disorder who were accepted or rejected for sex reassignment surgery: a prospective follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24275005" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Transsexual patients' psychiatric comorbidity and positive effect of cross-sex hormonal treatment on mental health: results from a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28945902" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28945902" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28945902" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28945902" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286768" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hormone treatment of the adult transsexual patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21449788" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical practice. Care of transsexual persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28090436" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33558672" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Contraception across transgender.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28914501" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Andrology of male-to-female transsexuals: influence of cross-sex hormone therapy on testicular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29808166" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Spermatogenesis Abnormalities following Hormonal Therapy in Transwomen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30092303" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effects of Feminizing Hormones on Sperm Production and Malignant Changes: Microscopic Examination of Post Orchiectomy Specimens in Transwomen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36652919" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Successful restoration of spermatogenesis following gender-affirming hormone therapy in transgender women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16204370" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Endogenous progesterone and the exogenous progestin norethisterone enanthate are associated with a proinflammatory profile in healthy men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31234145" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915619" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12917087" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Endocrinologic treatment of gender identity disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4831127" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Spironolactone and testicular cytochrome P-450: decreased testosterone formation in several species and changes in hepatic drug metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/984618" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Spironolactone and endocrine dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1176584" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of spironolactone on sex hormones in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19509099" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16320157" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29688280" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36007714" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Progestogen Use in Gender-Affirming Hormone Therapy: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34125226" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33471729" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : SERUM HORMONE CONCENTRATIONS IN TRANSGENDER INDIVIDUALS RECEIVING GENDER-AFFIRMING HORMONE THERAPY: A LONGITUDINAL RETROSPECTIVE COHORT STUDY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9373456" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mortality and morbidity in transsexual subjects treated with cross-sex hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671159" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23944849" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21266549" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9578826" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994752" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15502960" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cortical and trabecular bone mineral density in transsexuals after long-term cross-sex hormonal treatment: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30626577" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29763574" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : How low can you go? Analytical performance of five automated testosterone immunoassays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35964859" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Potassium Concentrations in Transgender Women Using Spironolactone: A Retrospective Chart Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25796182" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27561756" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29708436" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : PROLACTIN LEVELS DO NOT RISE AMONG TRANSGENDER WOMEN TREATED WITH ESTRADIOL AND SPIRONOLACTONE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33471679" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Differential Endocrine and Metabolic Effects of Testosterone Suppressive Agents in Transgender Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33648944" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : How does hormone transition in transgender women change body composition, muscle strength and haemoglobin? Systematic review with a focus on the implications for sport participation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14510900" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Endocrine intervention for transsexuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23682909" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Men and women, so different, so similar: observations from cross-sex hormone treatment of transsexual subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17986639" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10946903" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18835591" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Body composition, volumetric and areal bone parameters in male-to-female transsexual persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32685379" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effects of gender affirming hormone therapy on body mass index in transgender individuals: A longitudinal cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23317384" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Transgender voice and communication treatment: a retrospective chart review of 25 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10965175" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Speech therapy in the management of male-to-female transsexuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hormone therapy in adults: suggested revisions to the sixth version of the standards of care</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20092545" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Sexual functioning in transsexuals following hormone therapy and genital surgery: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33644622" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hormone Therapy, Mental Health, and Quality of Life Among Transgender People: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31327665" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Bone Densitometry in Transgender and Gender Non-Conforming (TGNC) Individuals: 2019 ISCD Official Position.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23904280" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22906135" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Long-term evaluation of cross-sex hormone treatment in transsexual persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24616414" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31656099" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Gender-Affirming Hormone Therapy, Vascular Health and Cardiovascular Disease in Transgender Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28738421" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28945852" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30776252" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17986639" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19473174" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34235936" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Assessing and Addressing Cardiovascular Health in People Who Are Transgender and Gender Diverse: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31372078" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34880832" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Risk of Venous Thromboembolism in Transgender People Undergoing Hormone Feminizing Therapy: A Prevalence Meta-Analysis and Meta-Regression Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29987313" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33417686" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : No Venous Thromboembolism Increase Among Transgender Female Patients Remaining on Estrogen for Gender-Affirming Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12763274" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33193106" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A Comprehensive Update on the Chylomicronemia Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26789855" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Mortality Among Veterans with Transgender-Related Diagnoses in the Veterans Health Administration, FY2000-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34481559" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34481557" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Health disparities in transgender people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24468761" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Transgenderism and reproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25254620" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Fertility preservation in the transgender patient: expanding oncofertility care beyond cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34144898" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Reproductive functions and fertility preservation in transgender women: a French case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32797184" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Fertility Options for the Transgender and Gender Nonbinary Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29699760" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Desire to Have Children Among Transgender People in Germany: A Cross-Sectional Multi-Center Study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
